Bridging the “Valley of Death” with Modern Clinical Drug Development: AACR President Patricia M. LoRusso addressed this topic in a keynote address to close the AACR Special Conference on Optimizing Therapeutic Efficacy and Tolerability through Cancer Chemistry. #AACRchem24 #AACRCICR
Paul Workman, Sharad Verma, Timothy A. Yap, and Jerome Mettetal discussed "Developing Efficacious Drugs with Better Combinability" in a plenary session at the AACR Conference on Optimizing Therapeutic Efficacy and Tolerability through Cancer Chemistry. #AACRchem24 #AACRCICR
Paul Workman highlighted the importance of selectivity towards the protein target of interest – both for modern, molecularly-targeted drugs and also for high-quality chemical probes for use in laboratory exploration of protein function. #AACRchem24
@icrlondon.bsky.social
@mdanderson.bsky.social
I really enjoyed chairing the #AACRCICR session today focused on bivalent degraders. Thank you to Michael Erb, Mikko Taipale, and Xin Zhou for the beautiful talks! #AACRchem24
Redefining Cancer Treatment with Tumor Targeted Modalities:
Puja Sapra addressed this topic in a keynote session to open the AACR Special Conference on Optimizing Therapeutic Efficacy and Tolerability through Cancer Chemistry. #AACRchem24 #AACRCICR
🧪 How can we develop efficacious drugs with better combinability? Join Paul Workman, Timothy A. Yap & Jerome Mettetal at @AACR’s #AACRchem24 conference (Dec 9–11) as they tackle this critical topic. Learn more: bit.ly/4gLZMYO
